Prevalence and impact of high platelet reactivity in chronic kidney disease: Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry

Usman Baber, Roxana Mehran, Ajay J. Kirtane, Paul A. Gurbel, Georgios Christodoulidis, Akiko Maehara, Bernhard Witzenbichler, Giora Weisz, Michael J. Rinaldi, D. Christopher Metzger, Timothy D. Henry, David A. Cox, Peter L. Duffy, Ernest L. Mazzaferri, Ke Xu, Helen Parise, Bruce R. Brodie, Thomas D. Stuckey, Gregg W. Stone

Research output: Contribution to journalArticle

Abstract

Chronic kidney disease (CKD) is associated with increased rates of adverse events after percutaneous coronary intervention. We sought to determine the impact of CKD on platelet reactivity in clopidogrel-treated patients and whether high platelet reactivity (HPR) confers a similar or differential risk for adverse events among patients with CKD and non-CKD. Methods and Results-We performed a post hoc analysis of the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) registry, which included 8582 patients undergoing percutaneous coronary intervention with drug-eluting stents and platelet function testing using the VerifyNow assay. We compared HPR and its impact on ischemic and bleeding events >2 years among patients with CKD and non-CKD. Patients with CKD (n=1367) were older, more often female, diabetic, and had lower ejection fraction compared with their non-CKD counterparts (n=7043). Although HPR prevalence increased with worsening renal function in unadjusted analyses, these associations were no longer present after adjustment. Major adverse cardiac event rates at 2 years among those without CKD or HPR, HPR alone, CKD alone, and both CKD and HPR were 9.0%, 11.2%, 13.3%, and 17.5%, respectively (P

Original languageEnglish (US)
Article numbere001683
JournalCirculation: Cardiovascular Interventions
Volume8
Issue number6
DOIs
StatePublished - Jun 20 2015

Fingerprint

Drug-Eluting Stents
Chronic Renal Insufficiency
Registries
Blood Platelets
Kidney Diseases
clopidogrel
Percutaneous Coronary Intervention
Therapeutics
Hemorrhage
Kidney

Keywords

  • Blood platelet
  • kidney
  • stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prevalence and impact of high platelet reactivity in chronic kidney disease : Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry. / Baber, Usman; Mehran, Roxana; Kirtane, Ajay J.; Gurbel, Paul A.; Christodoulidis, Georgios; Maehara, Akiko; Witzenbichler, Bernhard; Weisz, Giora; Rinaldi, Michael J.; Metzger, D. Christopher; Henry, Timothy D.; Cox, David A.; Duffy, Peter L.; Mazzaferri, Ernest L.; Xu, Ke; Parise, Helen; Brodie, Bruce R.; Stuckey, Thomas D.; Stone, Gregg W.

In: Circulation: Cardiovascular Interventions, Vol. 8, No. 6, e001683, 20.06.2015.

Research output: Contribution to journalArticle

Baber, U, Mehran, R, Kirtane, AJ, Gurbel, PA, Christodoulidis, G, Maehara, A, Witzenbichler, B, Weisz, G, Rinaldi, MJ, Metzger, DC, Henry, TD, Cox, DA, Duffy, PL, Mazzaferri, EL, Xu, K, Parise, H, Brodie, BR, Stuckey, TD & Stone, GW 2015, 'Prevalence and impact of high platelet reactivity in chronic kidney disease: Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry', Circulation: Cardiovascular Interventions, vol. 8, no. 6, e001683. https://doi.org/10.1161/CIRCINTERVENTIONS.115.001683
Baber, Usman ; Mehran, Roxana ; Kirtane, Ajay J. ; Gurbel, Paul A. ; Christodoulidis, Georgios ; Maehara, Akiko ; Witzenbichler, Bernhard ; Weisz, Giora ; Rinaldi, Michael J. ; Metzger, D. Christopher ; Henry, Timothy D. ; Cox, David A. ; Duffy, Peter L. ; Mazzaferri, Ernest L. ; Xu, Ke ; Parise, Helen ; Brodie, Bruce R. ; Stuckey, Thomas D. ; Stone, Gregg W. / Prevalence and impact of high platelet reactivity in chronic kidney disease : Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry. In: Circulation: Cardiovascular Interventions. 2015 ; Vol. 8, No. 6.
@article{fc4f14bc8bd54f78b414c531a7d1fcf9,
title = "Prevalence and impact of high platelet reactivity in chronic kidney disease: Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry",
abstract = "Chronic kidney disease (CKD) is associated with increased rates of adverse events after percutaneous coronary intervention. We sought to determine the impact of CKD on platelet reactivity in clopidogrel-treated patients and whether high platelet reactivity (HPR) confers a similar or differential risk for adverse events among patients with CKD and non-CKD. Methods and Results-We performed a post hoc analysis of the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) registry, which included 8582 patients undergoing percutaneous coronary intervention with drug-eluting stents and platelet function testing using the VerifyNow assay. We compared HPR and its impact on ischemic and bleeding events >2 years among patients with CKD and non-CKD. Patients with CKD (n=1367) were older, more often female, diabetic, and had lower ejection fraction compared with their non-CKD counterparts (n=7043). Although HPR prevalence increased with worsening renal function in unadjusted analyses, these associations were no longer present after adjustment. Major adverse cardiac event rates at 2 years among those without CKD or HPR, HPR alone, CKD alone, and both CKD and HPR were 9.0{\%}, 11.2{\%}, 13.3{\%}, and 17.5{\%}, respectively (P",
keywords = "Blood platelet, kidney, stents",
author = "Usman Baber and Roxana Mehran and Kirtane, {Ajay J.} and Gurbel, {Paul A.} and Georgios Christodoulidis and Akiko Maehara and Bernhard Witzenbichler and Giora Weisz and Rinaldi, {Michael J.} and Metzger, {D. Christopher} and Henry, {Timothy D.} and Cox, {David A.} and Duffy, {Peter L.} and Mazzaferri, {Ernest L.} and Ke Xu and Helen Parise and Brodie, {Bruce R.} and Stuckey, {Thomas D.} and Stone, {Gregg W.}",
year = "2015",
month = "6",
day = "20",
doi = "10.1161/CIRCINTERVENTIONS.115.001683",
language = "English (US)",
volume = "8",
journal = "Circulation: Cardiovascular Interventions",
issn = "1941-7640",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Prevalence and impact of high platelet reactivity in chronic kidney disease

T2 - Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry

AU - Baber, Usman

AU - Mehran, Roxana

AU - Kirtane, Ajay J.

AU - Gurbel, Paul A.

AU - Christodoulidis, Georgios

AU - Maehara, Akiko

AU - Witzenbichler, Bernhard

AU - Weisz, Giora

AU - Rinaldi, Michael J.

AU - Metzger, D. Christopher

AU - Henry, Timothy D.

AU - Cox, David A.

AU - Duffy, Peter L.

AU - Mazzaferri, Ernest L.

AU - Xu, Ke

AU - Parise, Helen

AU - Brodie, Bruce R.

AU - Stuckey, Thomas D.

AU - Stone, Gregg W.

PY - 2015/6/20

Y1 - 2015/6/20

N2 - Chronic kidney disease (CKD) is associated with increased rates of adverse events after percutaneous coronary intervention. We sought to determine the impact of CKD on platelet reactivity in clopidogrel-treated patients and whether high platelet reactivity (HPR) confers a similar or differential risk for adverse events among patients with CKD and non-CKD. Methods and Results-We performed a post hoc analysis of the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) registry, which included 8582 patients undergoing percutaneous coronary intervention with drug-eluting stents and platelet function testing using the VerifyNow assay. We compared HPR and its impact on ischemic and bleeding events >2 years among patients with CKD and non-CKD. Patients with CKD (n=1367) were older, more often female, diabetic, and had lower ejection fraction compared with their non-CKD counterparts (n=7043). Although HPR prevalence increased with worsening renal function in unadjusted analyses, these associations were no longer present after adjustment. Major adverse cardiac event rates at 2 years among those without CKD or HPR, HPR alone, CKD alone, and both CKD and HPR were 9.0%, 11.2%, 13.3%, and 17.5%, respectively (P

AB - Chronic kidney disease (CKD) is associated with increased rates of adverse events after percutaneous coronary intervention. We sought to determine the impact of CKD on platelet reactivity in clopidogrel-treated patients and whether high platelet reactivity (HPR) confers a similar or differential risk for adverse events among patients with CKD and non-CKD. Methods and Results-We performed a post hoc analysis of the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) registry, which included 8582 patients undergoing percutaneous coronary intervention with drug-eluting stents and platelet function testing using the VerifyNow assay. We compared HPR and its impact on ischemic and bleeding events >2 years among patients with CKD and non-CKD. Patients with CKD (n=1367) were older, more often female, diabetic, and had lower ejection fraction compared with their non-CKD counterparts (n=7043). Although HPR prevalence increased with worsening renal function in unadjusted analyses, these associations were no longer present after adjustment. Major adverse cardiac event rates at 2 years among those without CKD or HPR, HPR alone, CKD alone, and both CKD and HPR were 9.0%, 11.2%, 13.3%, and 17.5%, respectively (P

KW - Blood platelet

KW - kidney

KW - stents

UR - http://www.scopus.com/inward/record.url?scp=84937547092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937547092&partnerID=8YFLogxK

U2 - 10.1161/CIRCINTERVENTIONS.115.001683

DO - 10.1161/CIRCINTERVENTIONS.115.001683

M3 - Article

C2 - 26056248

AN - SCOPUS:84937547092

VL - 8

JO - Circulation: Cardiovascular Interventions

JF - Circulation: Cardiovascular Interventions

SN - 1941-7640

IS - 6

M1 - e001683

ER -